Medicus Pharma: A New Era in Cardio-Sparing Prostate Cancer Treatment
Medicus Pharma is developing a cardio-sparing hormone therapy for prostate cancer patients—targeting both cancer and heart safety.
Reimagining hormone therapy for men with advanced prostate cancer and heart risk
Advanced-stage prostate cancer affects up to 500,000 men in the U.S., many of whom also face a significant secondary risk: heart disease. Most current hormone therapies carry cardiovascular concerns—but Medicus Pharma is aiming to change that.
With a focus on cardio-oncology, Medicus is working on a new hormone therapy intended to reduce heart strain while maintaining efficacy in cancer treatment. Backed by a team that previously brought a breakthrough skin cancer patch to market, the company is now addressing a $4 billion opportunity in prostate cancer care. Their goal: safer outcomes for patients managing two life-threatening conditions.
For more information on Medicus Pharma (NASDAQ: MDCX) please click on the request investor info button.
Latest Articles
Hot Companies
You might also like
Volta Metals: Powering the Future with Ontario’s Critical Minerals
As global demand for critical minerals surges, Volta Metals is strategically positioned in Northwestern Ontario, exploring lithium and rare metals in proximity to infrastructure and clean energy sources.
.png)
.png)
